Industry Newsbiotechbridgebioanalyst ratings
Analysts Raise Price Targets For BridgeBio Pharma
5.1
BridgeBio Pharma (NASDAQ:BBIO) received updated analyst coverage in late January and early February 2026, with Barclays initiating an Overweight rating at a $157 price target on Jan. 27 and Bank of America raising its target to $88 on Feb. 3 (from $85) while maintaining a Buy. Analysts cited biotech sector tailwinds and expected M&A, though pre-announcements may mute the company’s upcoming Q4 market impact.
Key Points
- 1Bank of America raises BridgeBio price target to $88 on Feb 3; Barclays starts Overweight at $157
- 2Analysts cite biotech industry tailwinds, expected M&A activity, and solid fundamentals fueling 2026 optimism
- 3Investors should expect muted Q4 stock reaction due to pre-announcements and tempered market expectations
Scoring Rationale
Analyst upgrades provide credible, actionable investor signals; limited novelty and low relevance to AI/ML audiences reduce broader impact.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
